Novo Nordisk A/S
SWB:NOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novo Nordisk A/S
SWB:NOV
|
DK |
|
Yojee Ltd
F:SRC
|
AU |
|
Avolta AG
SIX:AVOL
|
CH |
|
Nippon Kayaku Co Ltd
OTC:NPKYF
|
JP |
|
S
|
Stepan Co
F:96S
|
US |
|
Unico Silver Ltd
OTC:USLRF
|
AU |
|
Bravura Solutions Ltd
ASX:BVS
|
AU |
|
T
|
Tyler Technologies Inc
F:TYP
|
US |
|
A
|
Aecon Group Inc
XMUN:2AE
|
CA |
|
H
|
Huntington Bancshares Inc
F:HU3
|
US |
|
Hitachi Construction Machinery Co Ltd
OTC:HTCMF
|
JP |
|
T
|
Tx Group Ltd
SIX:TXGN
|
CH |
|
B
|
Booz Allen Hamilton Holding Corp
F:BZ9
|
US |
|
Tesco PLC
LSE:TSCO
|
UK |
|
S
|
Shoprite Holdings Ltd
JSE:SHP
|
ZA |
|
Agatos SpA
F:5JS1
|
IT |
|
PTX Metals Inc
OTC:PANXF
|
CA |
|
S
|
Smart Concrete PCL
SET:SMART
|
TH |
|
L
|
Lindbergh SpA
MIL:LDB
|
IT |
|
Schindler Holding AG
SIX:SCHN
|
CH |
Intrinsic Value
Is NOV undervalued or overvalued?
See the intrinsic value estimate for 
Novo Nordisk A/S and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
NOV looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with NOV’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Novo Nordisk A/S Does
Novo Nordisk is a global drug company best known for medicines that treat diabetes and obesity. It also sells treatments for rare blood disorders, growth hormone deficiency, and other chronic diseases. The company does not make consumer products; it develops prescription medicines that doctors prescribe and patients use over long periods.
- Headquarters
- Denmark DK
- Employees
- 47 792
- IPO date
- May 17, 1974
Novo Nordisk A/S has a wide economic moat
Legal protection for key medicines prevents rivals from selling direct copies in major markets, helping Novo Nordisk keep profits from its diabetes and obesity treatments. Competitors must develop different medicines and prove they work rather than simply copy its protected products.
Read the full moat analysis
Revenue & Expenses Breakdown
Novo Nordisk A/S
Earnings Waterfall
Novo Nordisk A/S
The intrinsic value for Novo Nordisk A/S (NOV) under the Base Case is hidden EUR.
Compared with the current market price of 38.855 EUR, the stock appears hidden.